Chlamydial Protease-Like Activity Factor and Type III Secreted Effectors Cooperate in Inhibition of p65 Nuclear Translocation.
The chlamydial protease-like activity factor (CPAF) is hypothesized to be an important secreted virulence factor; however, challenges in denaturing its proteolytic activity have hampered attempts to identify its legitimate targets. Here, we use a genetic and proteomic approach to identify authentic CPAF targets. Human epithelial cells infected with CPAF-sufficient and CPAF-deficient chlamydiae were lysed using known CPAF-denaturing conditions. Their protein profiles were analyzed using isobaric mass tags and liquid chromatography-tandem mass spectrometry. Comparative analysis of CPAF-sufficient and CPAF-deficient infections identified a limited number of CPAF host and chlamydial protein targets. Host targets were primarily interferon-stimulated gene products, whereas chlamydial targets were type III secreted proteins. We provide evidence supporting a cooperative role for CPAF and type III secreted effectors in blocking NF-κB p65 nuclear translocation, resulting in decreased beta interferon and proinflammatory cytokine synthesis. Genetic complementation of null organisms with CPAF restored p65 nuclear translocation inhibition and proteolysis of chlamydial type III secreted effector proteins (T3SEs). We propose that CPAF and T3SEs cooperate in the inhibition of host innate immunity.


OBJECTIVE
Chlamydia trachomatis is an important human pathogen responsible for over 100 million infections each year worldwide. Its success as an intracellular pathogen revolves around its ability to evade host immunity. The chlamydial protease-like activity factor (CPAF) is a conserved serine protease secreted into the host cytosol of infected cells that is thought to play an important role in immune evasion. Currently, CPAF's authentic in situ target(s) and mechanism of action in immune evasion are poorly characterized. Using a CPAF-deficient strain and high-throughput proteomics, we report novel CPAF host and chlamydial targets. Host targets were primarily interferon-stimulated genes, whereas chlamydial targets were exclusively type III secreted proteins. We propose a novel mechanism for CPAF and type III secreted proteins in the evasion of host innate immune responses. These findings provide new insights into CPAF's function as a virulence factor and a better understanding of how chlamydiae evade host immunity.
Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Michael John
MJ
Patton
National Microbiology Laboratories, Winnipeg, Manitoba, Canada.
Stuart
S
McCorrister
National Microbiology Laboratories, Winnipeg, Manitoba, Canada.
Chris
C
Grant
National Microbiology Laboratories, Winnipeg, Manitoba, Canada.
Garrett
G
Westmacott
National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Robert
R
Fariss
Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Canada.
Pingzhao
P
Hu
Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Canada.
Kaiqiong
K
Zhao
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Mary
M
Blake
Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Bill
B
Whitmire
Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Chunfu
C
Yang
Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA hcaldwell@niaid.nih.gov Grant.McClarty@umanitoba.ca.
Harlan D
HD
Caldwell
National Microbiology Laboratories, Winnipeg, Manitoba, Canada hcaldwell@niaid.nih.gov Grant.McClarty@umanitoba.ca.
Grant
G
McClarty
Microbes Infect. 2016 Nov;18(11):669-674
27436813
Pathog Dis. 2014 Aug;71(3):336-51
24838663
PLoS Pathog. 2015 Jul 01;11(7):e1005013
26132339
Microbes Infect. 2015 Jun;17(6):402-8
25752416
Infect Immun. 2014 Jan;82(1):2-9
24126521
Infect Immun. 1995 Dec;63(12):4661-8
7591120
MBio. 2016 Jan 19;7(1):e01817-15
26787828
J Biol Chem. 2010 Dec 31;285(53):41320-7
21041296
Cell Host Microbe. 2008 Dec 11;4(6):529-42
19064254
Infect Immun. 1981 Mar;31(3):1161-76
7228399
Infect Immun. 2015 Jun;83(6):2234-41
25776755
Vaccine. 2013 Apr 8;31(15):1892-7
23375977
Mol Microbiol. 2011 Dec;82(5):1185-203
22014092
Microbiol Rev. 1991 Mar;55(1):143-90
2030670
J Proteome Res. 2015 Nov 6;14(11):4511-23
26381135
Curr Issues Mol Biol. 2010;12(1):17-41
19605938
Microb Pathog. 2010 Oct;49(4):164-73
20510344
Pathog Dis. 2015 Feb;73(1):1-8
25663342
Stat Appl Genet Mol Biol. 2004;3:Article3
16646809
Infect Immun. 2011 Feb;79(2):571-80
21078856
PLoS Pathog. 2016 May 27;12(5):e1005653
27232334
J Virol. 2011 Apr;85(7):3162-71
21270162
Nat Immunol. 2000 Sep;1(3):199-205
10973276
Nat Rev Immunol. 2015 Feb;15(2):87-103
25614319
Infect Immun. 2016 Aug 19;84(9):2697-702
27382018
Microbiol Mol Biol Rev. 2012 Jun;76(2):262-310
22688814
Microbiology. 2010 Oct;156(Pt 10):3031-40
20522495
J Immunol. 2007 Oct 1;179(7):4542-9
17878351
Cell Host Microbe. 2011 Jul 21;10(1):21-32
21767809
J Exp Med. 2001 Apr 16;193(8):935-42
11304554
J Virol. 2015 Nov;89(22):11534-48
26355085
Annu Rev Immunol. 2014;32:513-45
24555472
Structure. 2014 Jun 10;22(6):878-88
24856362
Infect Immun. 2002 Jun;70(6):2741-51
12010958